These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 36982693)

  • 1. Dopamine Transmission Imbalance in Neuroinflammation: Perspectives on Long-Term COVID-19.
    Mancini M; Natoli S; Gardoni F; Di Luca M; Pisani A
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Possible Link between SARS-CoV-2 Infection and Parkinson's Disease: The Role of Toll-Like Receptor 4.
    Conte C
    Int J Mol Sci; 2021 Jul; 22(13):. PubMed ID: 34281186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of SARS-CoV-2 on the development of Parkinson's disease: the role of α-synuclein.
    Iravanpour F; Farrokhi MR; Jafarinia M; Oliaee RT
    Hum Cell; 2024 Jan; 37(1):1-8. PubMed ID: 37735344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-COVID-19 Parkinsonism and Parkinson's Disease Pathogenesis: The Exosomal Cargo Hypothesis.
    Mysiris DS; Vavougios GD; Karamichali E; Papoutsopoulou S; Stavrou VT; Papayianni E; Boutlas S; Mavridis T; Foka P; Zarogiannis SG; Gourgoulianis K; Xiromerisiou G
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-COV-2 infection and Parkinson's disease: Possible links and perspectives.
    Al-Kuraishy HM; Al-Gareeb AI; Kaushik A; Kujawska M; Ahmed EA; Batiha GE
    J Neurosci Res; 2023 Jun; 101(6):952-975. PubMed ID: 36717481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review on the interactions between dopamine metabolites and α-Synuclein in causing Parkinson's disease.
    Sivakumar P; Nagashanmugam KB; Priyatharshni S; Lavanya R; Prabhu N; Ponnusamy S
    Neurochem Int; 2023 Jan; 162():105461. PubMed ID: 36460239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the Paradox of COVID-19 in Neurological Complications with Emphasis on Parkinson's and Alzheimer's Disease.
    Rai SN; Tiwari N; Singh P; Singh AK; Mishra D; Imran M; Singh S; Hooshmandi E; Vamanu E; Singh SK; Singh MP
    Oxid Med Cell Longev; 2022; 2022():3012778. PubMed ID: 36092161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein/synapsin III pathological interplay boosts the motor response to methylphenidate.
    Faustini G; Longhena F; Bruno A; Bono F; Grigoletto J; La Via L; Barbon A; Casiraghi A; Straniero V; Valoti E; Costantino G; Benfenati F; Missale C; Pizzi M; Spillantini MG; Bellucci A
    Neurobiol Dis; 2020 May; 138():104789. PubMed ID: 32032728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. alpha-Synuclein- and MPTP-generated rodent models of Parkinson's disease and the study of extracellular striatal dopamine dynamics: a microdialysis approach.
    Bazzu G; Calia G; Puggioni G; Spissu Y; Rocchitta G; Debetto P; Grigoletto J; Zusso M; Migheli R; Serra PA; Desole MS; Miele E
    CNS Neurol Disord Drug Targets; 2010 Aug; 9(4):482-90. PubMed ID: 20522009
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of alpha-synuclein aggregation by dopamine: a review.
    Leong SL; Cappai R; Barnham KJ; Pham CL
    Neurochem Res; 2009 Oct; 34(10):1838-46. PubMed ID: 19444607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-dependent neurodegeneration and neuroinflammation in a genetic A30P/A53T double-mutated α-synuclein mouse model of Parkinson's disease.
    Rauschenberger L; Behnke J; Grotemeyer A; Knorr S; Volkmann J; Ip CW
    Neurobiol Dis; 2022 Sep; 171():105798. PubMed ID: 35750147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Proteins Interact with Alpha Synuclein and Induce Lewy Body-like Pathology In Vitro.
    Wu Z; Zhang X; Huang Z; Ma K
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2-Mimicking Pseudoviral Particles Accelerate α-Synuclein Aggregation In Vitro.
    Zilio G; Masato A; Sandre M; Caregnato A; Moret F; Maciola AK; Antonini A; Brucale M; Cendron L; Plotegher N; Bubacco L
    ACS Chem Neurosci; 2024 Jan; 15(2):215-221. PubMed ID: 38131609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of Toll-like receptors and neuroinflammation in Parkinson's disease.
    Heidari A; Yazdanpanah N; Rezaei N
    J Neuroinflammation; 2022 Jun; 19(1):135. PubMed ID: 35668422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COVID-19 and Parkinsonism: A Critical Appraisal.
    Cavallieri F; Fioravanti V; Bove F; Del Prete E; Meoni S; Grisanti S; Zedde M; Pascarella R; Moro E; Valzania F
    Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential convergence of olfactory dysfunction in Parkinson's disease and COVID-19: The role of neuroinflammation.
    Li H; Qian J; Wang Y; Wang J; Mi X; Qu L; Song N; Xie J
    Ageing Res Rev; 2024 Jun; 97():102288. PubMed ID: 38580172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smell deficits in COVID-19 and possible links with Parkinson's disease.
    Emmi A; Sandre M; Porzionato A; Antonini A
    Int Rev Neurobiol; 2022; 165():91-102. PubMed ID: 36208908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroinflammation and α-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson's disease.
    Gao HM; Zhang F; Zhou H; Kam W; Wilson B; Hong JS
    Environ Health Perspect; 2011 Jun; 119(6):807-14. PubMed ID: 21245015
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex-specific biphasic alpha-synuclein response and alterations of interneurons in a COVID-19 hamster model.
    Schreiber CS; Wiesweg I; Stanelle-Bertram S; Beck S; Kouassi NM; Schaumburg B; Gabriel G; Richter F; Käufer C
    EBioMedicine; 2024 Jul; 105():105191. PubMed ID: 38865747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanistic Insight from Preclinical Models of Parkinson's Disease Could Help Redirect Clinical Trial Efforts in GDNF Therapy.
    Delgado-Minjares KM; Martinez-Fong D; Martínez-Dávila IA; Bañuelos C; Gutierrez-Castillo ME; Blanco-Alvarez VM; Cardenas-Aguayo MD; Luna-Muñoz J; Pacheco-Herrero M; Soto-Rojas LO
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.